The Association of Airway Comorbidities With the Clinical Phenotypes and Outcomes of Patients With Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis.


Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
03 2021
Historique:
accepted: 01 08 2019
pubmed: 17 9 2019
medline: 1 9 2021
entrez: 17 9 2019
Statut: ppublish

Résumé

We investigated the association of airway comorbidities with the clinical phenotypes and outcomes of myeloperoxidase (MPO)-antineutrophil cytoplasmic antibodies (ANCA)-positive ANCA-associated vasculitis (AAV). An AAV patient multicenter cohort trial was established in 13 hospitals in western Japan between 2012 and 2018. We examined 143 of the new-onset MPO-ANCA-positive AAV patients. Their clinical characteristics and comorbidities at disease onset were compared based on clinical phenotypes. Multivariate analysis was performed to identify factors predictive of remission and death. Twenty-seven cases with granulomatosis with polyangiitis (GPA), 10 with eosinophilic GPA (EGPA), 81 with microscopic polyangiitis (MPA), and 25 with unclassified AAV were identified. The average age of MPO-ANCA-positive patients was 71.4 years. Comorbidity (87.4%) and airway comorbidity (70.6%) were frequently observed in these patients. Examination of the clinical phenotypes revealed that the cases of GPA were frequently accompanied by infectious airway comorbidity (upper airway disease, bronchiectasis, pulmonary infections), and most of the cases of MPA and unclassified AAV were accompanied by fibrotic interstitial lung disease (fILD) or emphysema. Among MPO-ANCA-positive patients, infectious airway comorbidity was predictive of both remission (HR 1.58, MPO-ANCA-positive AAV was frequently accompanied by airway comorbidities. In addition to fILD, infectious airway comorbidities were closely associated with those clinical phenotypes and outcomes.

Identifiants

pubmed: 31523048
pii: jrheum.190373
doi: 10.3899/jrheum.190373
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
Peroxidase EC 1.11.1.7
Myeloblastin EC 3.4.21.76

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

417-425

Informations de copyright

Copyright © 2021 by the Journal of Rheumatology.

Auteurs

Nobuyuki Ono (N)

N. Ono, MD, PhD, Y. Sadanaga, MD, Y. Tada, MD, PhD, Department of Rheumatology, Faculty of Medicine, Saga University, Saga; nono@cc.saga-u.ac.jp.

Yasushi Inoue (Y)

Y. Inoue, MD, PhD, Department of Rheumatology, Fukuoka Red Cross Hospital.

Tomoya Miyamura (T)

T. Miyamura, MD, PhD, Department of Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka.

Naoyasu Ueda (N)

N. Ueda, MD, PhD, Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki.

Shuji Nagano (S)

S. Nagano, MD, Department of Rheumatology, Iizuka Hospital.

Hisako Inoue (H)

H. Inoue, MD, PhD, Department of Rheumatology, Saiseikai Fukuoka Hospital, Fukuoka.

Kensuke Oryoji (K)

K. Oryoji, MD, Department of Rheumatology, Matsuyama Red Cross Hospital, Matsuyama.

Shun-Ichiro Ota (SI)

S. Ota, MD, Department of Rheumatology, Shimonoseki City Hospital, Shimonoseki.

Takuya Sawabe (T)

T. Sawabe, MD, PhD, Department of Rheumatology, Hiroshima Red Cross Hospital, Hiroshima.

Seiji Yoshizawa (S)

S. Yoshizawa, MD, PhD, Department of Rheumatology, Hamanomachi Hospital, Fukuoka.

Yukiko Takeyama (Y)

Y. Takeyama, MD, Department of Rheumatology, Faculty of Medicine, Saga University, Saga, Department of Rheumatology, Saiseikai Karatsu Hospital, Karatsu.

Yuri Sadanaga (Y)

N. Ono, MD, PhD, Y. Sadanaga, MD, Y. Tada, MD, PhD, Department of Rheumatology, Faculty of Medicine, Saga University, Saga.

Ayako Takamori (A)

A. Takamori, MD, PhD, Clinical Research Center, Saga University Hospital, Saga.

Yasutaka Kimoto (Y)

Y. Kimoto, MD, T. Horiuchi, MD, PhD, Department of Rheumatology, Kyushu University Beppu Hospital, Beppu.

Katsuhisa Miyake (K)

K. Miyake, MD, PhD, H. Nakashima, MD, PhD, Department of Rheumatology, Fukuoka University.

Takahiko Horiuchi (T)

Y. Kimoto, MD, T. Horiuchi, MD, PhD, Department of Rheumatology, Kyushu University Beppu Hospital, Beppu.

Hitoshi Nakashima (H)

K. Miyake, MD, PhD, H. Nakashima, MD, PhD, Department of Rheumatology, Fukuoka University.

Hiroaki Niiro (H)

H. Niiro, MD, PhD, Department of Rheumatology, Kyushu University, Fukuoka, Japan.

Yoshifumi Tada (Y)

N. Ono, MD, PhD, Y. Sadanaga, MD, Y. Tada, MD, PhD, Department of Rheumatology, Faculty of Medicine, Saga University, Saga.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH